logo
Share SHARE
FONT-SIZE Plus   Neg

AMAG Pharmaceutocals Reveal Positive Results From Phase III Study Of Feraheme

AMAG Pharmaceuticals Inc (AMAG) Wednesday announced positive preliminary results from the second phase III study for Feraheme in patients with iron deficiency anemia or IDA, regardless of the underlying cause.

The biopharmaceutical company stated that the study, called as IDA-301, compared Feraheme treatment to placebo and enrolled patients having IDA associated with various conditions including abnormal uterine bleeding, cancer, gastrointestinal disorders or other causes.

The company further stated that Feraheme demonstrated superiority on all primary efficacy endpoints evaluated in this study.

The company added that the efficacy and safety of Feraheme in this study were comparable to that reported in the IDA-302 study, the phase III IDA study comparing Feraheme to iron sucrose.

In the IDA-301 study, Feraheme demonstrated robust efficacy, achieving superiority on both primary efficacy endpoints. Patients treated with Feraheme achieved a statistically significant mean increase in hemoglobin at week five of 2.7 g/dL, compared to a mean increase of only 0.1 g/dL in patients who received placebo; importantly, these data are consistent with the 2.7 g/dL increase in hemoglobin reported in the IDA-302 study,

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Sanofi SA were gaining around 2 percent in the early morning trading in Paris after the French drug giant reported significantly higher profit in its first quarter, benefited by 4.4 billion euros gains from the disposal of its Merial animal healthcare unit and higher sales. For fiscal 2017, Sanofi said it continues to expect Business earnings per share to be stable to negative 3 percent. Shares of UBS Group AG were gaining around 4 percent in the early morning trading after the Swiss banking giant reported Friday significantly higher profit in its first quarter, despite weakness in net interest income. The company also proposed a dividend. Looking ahead, UBS said it is well positioned to mitigate various market challenges... Alphabet Inc. (GOOG, GOOGL), the parent company of Google, Thursday reported an increase in profit for the first quarter, driven largely revenue growth in search and advertising. Alphabet's first-quarter profit rose to $5.43 billion or $7.73 per share from $4.21 billion or $6.02 per share last year. On...
comments powered by Disqus
Follow RTT